Core Insights - BioNxt Solutions Inc. has made significant progress in its proprietary cladribine oral thin film (ODF) program, achieving a greater than 40% improvement in bioavailability compared to conventional formulations [1] Company Developments - The recent study results represent a key development milestone for the company, supporting its transition toward human clinical evaluation [1]